ArticleJCO precision oncology2022
Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07343024 (Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients), which is not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- The implementation of Next-Generation Sequencing (NGS) in a Brazilian Public Hospital: a systematic review of challenges and perspectives in oncology.BMC medical genomics · 2026Pooled it
- Implementation of precision medicine in treating non-communicable diseases: a systematic review.Journal of translational medicine · 2025Pooled it
- Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework.JCO precision oncology · 2025Pooled it
- Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.Journal of the National Cancer Institute · 2024Pooled it
- Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.Nature medicine · 2024Trial
- Cancer Survival at a Comprehensive Cancer Center Compared With Surveillance, Epidemiology, and End Results (SEER) Estimates.American journal of medicine open · 2026Article
- Payer coverage principles for precision medicine biomarker testing in oncology.Journal of managed care & specialty pharmacy · 2026Article
- A predictive model for fusion gene positivity in treatment-naive advanced non-small cell lung cancer.Translational lung cancer research · 2026Article
- Clinical harm from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer.Journal of managed care & specialty pharmacy · 2026Article
- Standardized protocols for reflexing to a multigene panel for patients with non-small cell lung cancer: prevalence and perceived barriers to comprehensive, pathologist-ordered biomarker reflex testing.American journal of clinical pathology · 2026Article
- Successful simplified genomic profiling of cytology specimens using Aspyre Clinical Test for Lung (Tissue).Cancer cytopathology · 2026Article
- Findings from the 2025 AMCP Foundation Symposium: Health Optimization 2.0.Journal of managed care & specialty pharmacy · 2026Article
- Article
- Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program.The oncologist · 2026Article
- Review
- Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer.JCO oncology practice · 2026Article
- Validation of histopathology-based deep learning algorithms for detection of actionable non-small cell lung cancer biomarkers.NPJ precision oncology · 2026Article
- A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid Leukemia.Research square · 2026Article
- Toward a National Health Digital and Data Architecture: Laying the Foundation for Digital Transformation: Commission on Investment Imperatives for a Healthy Nation.NAM perspectives · 2026Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePersonalized medicine presents new opportunities for patients with cancer. However, many patients do not receive the most effective personalized treatments because of challenges associated with integrating predictive biomarker testing into clinical care. Patients are lost at various steps along the precision oncology pathway because of operational inefficiencies, limited understanding of biomarker strategies, inappropriate testing result usage, and access barriers. We examine the impact of various clinical practice gaps associated with diagnostic testing-informed personalized medicine strategies on the treatment of advanced non-small-cell lung cancer (aNSCLC).
methodsUsing Diaceutics' Data Repository, a multisource database including commercial and Medicare claims and laboratory data from over 500,000 patients with non-small-cell lung cancer in the United States, we analyzed the number of patients with newly diagnosed aNSCLC who could have, but did not, benefit from a personalized treatment. The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment.
resultsFor every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of 1,000 patients who did receive results from a biomarker test, 147 (29.2%) did not receive appropriate targeted treatments. Thus, approximately 64% of potentially eligible patients with aNSCLC are not benefiting from precision oncology therapies appropriate for their disease.
conclusionMost patients with aNSCLC eligible for precision oncology treatments do not benefit from them because of clinical practice gaps. This finding is likely reflective of similar gaps in other cancer types. An increased understanding of the impact of each practice gap can inform strategies to improve the delivery of precision oncology, helping to fully realize the promise of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.